Barca's latest signee, Emerson Royale underwent his medical at the club facilities earlier today. The Brazilian star also participated in his first training session as a player of the club.
See photos from the training sessions below:
Photo credit: Twitter/@FCBarcelona
Emerson Royale was bought from Real Betis for a reported fee of £9 million this summer. During his time at Real Betis, the Brazilian International established himself as one of the best right-backs in the league.
Last season, Emerson played 34 games in LA Liga Santander. He accumulated a total of 2993 minutes in which he scored a goal and gave 4 assists.
Emerson Royale is surely a big boost for FC Barcelona. He's expected to provide competition for Sergi Roberto and Sergino Dest in the right-back positions.
His formal presentation is expected to take place on August 5th or 6th, after Barca's friendly vs Salzburg, but August 3rd is also not ruled out.
Drop your comments below.
Content created and supplied by: Dozz (via Opera News )
Opera News is a free to use platform and the views and opinions expressed herein are solely those of the author and do not represent, reflect or express the views of Opera News. Any/all written content and images displayed are provided by the blogger/author, appear herein as submitted by the blogger/author and are unedited by Opera News. Opera News does not consent to nor does it condone the posting of any content that violates the rights (including the copyrights) of any third party, nor content that may malign, inter alia, any religion, ethnic group, organization, gender, company, or individual. Opera News furthermore does not condone the use of our platform for the purposes encouraging/endorsing hate speech, violation of human rights and/or utterances of a defamatory nature. If the content contained herein violates any of your rights, including those of copyright, and/or violates any the above mentioned factors, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com and/or report the article using the available reporting functionality built into our Platform See More